198 related articles for article (PubMed ID: 37794185)
21. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
22. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
23. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
24. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
25. PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.
Wiede F; Ziegler A; Zehn D; Tiganis T
J Autoimmun; 2014 Sep; 53():105-14. PubMed ID: 24997008
[TBL] [Abstract][Full Text] [Related]
26. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
27. Effects of exercise and anti-PD-1 on the tumour microenvironment.
Buss LA; Williams T; Hock B; Ang AD; Robinson BA; Currie MJ; Dachs GU
Immunol Lett; 2021 Nov; 239():60-71. PubMed ID: 34480981
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
29. CD4
Kruse B; Buzzai AC; Shridhar N; Braun AD; Gellert S; Knauth K; Pozniak J; Peters J; Dittmann P; Mengoni M; van der Sluis TC; Höhn S; Antoranz A; Krone A; Fu Y; Yu D; Essand M; Geffers R; Mougiakakos D; Kahlfuß S; Kashkar H; Gaffal E; Bosisio FM; Bechter O; Rambow F; Marine JC; Kastenmüller W; Müller AJ; Tüting T
Nature; 2023 Jun; 618(7967):1033-1040. PubMed ID: 37316667
[TBL] [Abstract][Full Text] [Related]
30. A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity.
Liang S; Tran E; Du X; Dong J; Sudholz H; Chen H; Qu Z; Huntington N; Babon J; Kershaw N; Zhang ZY; Baell J; Wiede F; Tiganis T
bioRxiv; 2023 Jun; ():. PubMed ID: 37397992
[TBL] [Abstract][Full Text] [Related]
31. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
[TBL] [Abstract][Full Text] [Related]
32. Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy.
Zuazo M; Arasanz H; Bocanegra A; Fernandez G; Chocarro L; Vera R; Kochan G; Escors D
Front Immunol; 2020; 11():586907. PubMed ID: 33329566
[TBL] [Abstract][Full Text] [Related]
33. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
[TBL] [Abstract][Full Text] [Related]
35. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
36. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
37. Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers.
Tata A; Dodard G; Fugère C; Leget C; Ors M; Rossi B; Vivier E; Brossay L
Oncoimmunology; 2021 Jun; 10(1):1933808. PubMed ID: 34188973
[TBL] [Abstract][Full Text] [Related]
38. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
39. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
40. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
Front Immunol; 2021; 12():773168. PubMed ID: 35003090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
